Viva Star Biosciences is a clinical-stage biotech company dedicated to the discovery, development and commercialization of innovative therapies for age-related debilitating diseases (e.g., pulmonary fibrosis, renal interstitial fibrosis, systemic sclerosis) caused by inflammation and tissue fibrosis. The company’s R&D strategy centers around novel molecular targets involved in signal transduction pathways important for the activation of myofibroblasts, with a particular emphasis on the interplay among immunometabolism, inflammation, fibrogenesis and cell death. This integrated approach aims to identify and enhance the therapeutic potential of novel modalities that can be used as a single agent or in combination.

Viva Star Bio is led by an industrial veteran with rich experiences in academic research, pharma R&D, venture capital investment and entrepreneurship. Company’s R&D team is consisted of accomplished individuals with deep domain expertise ranging from disease biology, medicinal chemistry, preclinical safety and ADME, regulatory sciences, to clinical development. 
Viva Star Bio is advancing proprietary and differentiated assets addressing unmet medical needs in inflammatory disorders and fibrotic diseases.